|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
PSYGENET |
Between-gene interactions including DAO*DISC1 , DAO*NRG1 and DAO*RASD2 and a within-gene interaction for CACNG2 were found among schizophrenia subjects with severe sustained attention deficits, suggesting a modifying effect of impaired neuropsychological functioning.
|
23555897 |
2013 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
BEFREE |
Between-gene interactions including DAO*DISC1 , DAO*NRG1 and DAO*RASD2 and a within-gene interaction for CACNG2 were found among schizophrenia subjects with severe sustained attention deficits, suggesting a modifying effect of impaired neuropsychological functioning.
|
23555897 |
2013 |
|
Schizophrenia
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Three of five candidate vulnerability genes (RASD2, APOL5, MYH9, EIF3S7, and CACNG2), which had marginally significant associations with schizophrenia, had significant associations with schizophrenic patients who did not have deficits in sustained attention on the undegraded CPT (RASD2 gene SNP rs736212; p = .0008 with single locus analysis) and the degraded CPT (MYH9 gene haplotype 1-1-1-1 of SNP rs3752463 - rs1557540 - rs713839 - rs739097; p = .0059 with haplotype analysis).
|
18571626 |
2008 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
PSYGENET |
We aimed to examine the expression levels of Stargazin in post-mortem brain samples of patients with schizophrenia, patients with bipolar disorder (BPD) and healthy controls, test for genetic association between Stargazin and these disorders and test for genetic association between Stargazin and response to lithium treatment.
|
18408563 |
2008 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
BEFREE |
We aimed to examine the expression levels of Stargazin in post-mortem brain samples of patients with schizophrenia, patients with bipolar disorder (BPD) and healthy controls, test for genetic association between Stargazin and these disorders and test for genetic association between Stargazin and response to lithium treatment.
|
18408563 |
2008 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
PSYGENET |
Three of five candidate vulnerability genes (RASD2, APOL5, MYH9, EIF3S7, and CACNG2), which had marginally significant associations with schizophrenia, had significant associations with schizophrenic patients who did not have deficits in sustained attention on the undegraded CPT (RASD2 gene SNP rs736212; p = .0008 with single locus analysis) and the degraded CPT (MYH9 gene haplotype 1-1-1-1 of SNP rs3752463 - rs1557540 - rs713839 - rs739097; p = .0059 with haplotype analysis).
|
18571626 |
2008 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
BEFREE |
A recent report has suggested that copy number variations in four genes (GRIK3, EFNA5, AKAP5 and CACNG2) may be associated with schizophrenia.
|
17826036 |
2007 |
|
Schizophrenia
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
In situ hybridization for AMPA-trafficking molecules showed decreased expression of PICK1 and increased expression of stargazin in DLPFC in schizophrenia, both restricted to large cells of cortical layer III.
|
16983646 |
2006 |